US Senator
Amy Klobuchar 2025-2026 Regular Session - Authored & Sponsored Legislation (Page 2)
Legislative Session
Primary Sponsor of Legislation
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1096
Introduced
3/24/25
Refer
3/24/25
Report Pass
4/3/25
Preserve Access to Affordable Generics and Biosimilars Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1177
Introduced
3/27/25
Refer
3/27/25
Volunteer Driver Tax Appreciation Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1213
Introduced
3/31/25
Refer
3/31/25
Protect Elections from Deceptive AI Act
Co-Sponsor of Legislation
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1098
Introduced
3/24/25
Refer
3/24/25
Report Pass
7/24/25
Opioid Overdose Data Collection Enhancement Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1115
Introduced
3/25/25
Refer
3/25/25
Paycheck Fairness Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1133
Introduced
3/26/25
Refer
3/26/25
Sunshine in the Courtroom Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1144
Introduced
3/26/25
Refer
3/26/25
PHIT Act of 2025 Personal Health Investment Today Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1146
Introduced
3/26/25
Refer
3/26/25
Cameras in the Courtroom Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1154
Introduced
3/26/25
Refer
3/26/25
Congressional Whistleblower Protection Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1156
Introduced
3/26/25
Refer
3/26/25
Food Secure Strikers Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1163
Introduced
3/27/25
Refer
3/27/25
Rural Veterinary Workforce Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1186
Introduced
3/27/25
Refer
3/27/25
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1193
Introduced
3/27/25
Refer
3/27/25
America’s Red Rock Wilderness Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1209
Introduced
3/31/25
Refer
3/31/25
American Prairie Conservation Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB1227
Introduced
4/1/25
Refer
4/1/25
ABC Act Alleviating Barriers for Caregivers Act